ArticleValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2018
Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping.
Article in Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mapping to estimate health state utility: a systematic review of development and limitations.Health and quality of life outcomes · 2025Pooled it
- Mapping of the EORTC QLQ-LC43 to EQ-5D-5 L index in patients with lung cancer: comparison of traditional regression models with machine learning technique.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Mapping Health State Utility from Disease-Specific Measures in Spinal Muscular Atrophy and Paroxysmal Nocturnal Hemoglobinuria.PharmacoEconomics · 2026Article
- Development of mapping algorithms for gastric cancer: translating EORTC QLQ-C30 and QLQ-STO22 to EQ-5D-5L health utilities.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Mapping the ADDQoL to the EQ-5D-5L and SF-6Dv2 among Chinese patients with type 2 diabetes mellitus.Health and quality of life outcomes · 2025Article
- Developing mapping algorithms to predict EQ-5D health utility values from Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index among patients with Ankylosing Spondylitis.Health and quality of life outcomes · 2024Article
- Mapping the EORTC QLQ-C30 and QLQ H&N35 to the EQ-5D-5L and SF-6D for papillary thyroid carcinoma.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Mapping Short Warwick and Edinburgh Mental Wellbeing Scale (SWEMWBS) to Recovering Quality of Life (ReQoL) to estimate health utilities.Health and quality of life outcomes · 2024Article
- Prediction of the SF-6D utility score from Lung cancer FACT-L: a mapping study in China.Health and quality of life outcomes · 2023Article
- Mapping of disease-specific Oxford Knee Score onto EQ-5D-5L utility index in knee osteoarthritis.Journal of orthopaedic surgery and research · 2023Article
- Mapping the Patient-Reported Outcomes Measurement Information System (PROMIS-29) to EQ-5D-5L.PharmacoEconomics · 2023Article
- Mapping study of papillary thyroid carcinoma in China: Predicting EQ-5D-5L utility values from FACT-H&N.Frontiers in public health · 2023Article
- Mapping health assessment questionnaire disability index onto EQ-5D-5L in China.Frontiers in public health · 2023Article
- Mapping the Haem-A-QoL to the EQ-5D-5L in patients with hemophilia.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022Article
- Article
- Mapping the PHQ-8 to EQ-5D, HUI3 and SF6D in patients with depression.BMC psychiatry · 2021Article
- Mapping the cancer-specific FACT-B onto the generic SF-6Dv2.Breast cancer (Tokyo, Japan) · 2021Article
- Mapping of the EORTC QLQ-C30 to EQ-5D-5L index in patients with lymphomas.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Article
- Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer.Health and quality of life outcomes · 2020Article
- Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods.Health technology assessment (Winchester, England) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundPreference-based measures of health, such as the three-level EuroQol five-dimensional questionnaire (EQ-5D-3L), are required to calculate quality-adjusted life-years for use in cost-effectiveness analysis, but are often not recorded in clinical studies. In these cases, mapping can be used to estimate preference-based measures.
objectivesTo model the relationship between the EQ-5D-3L and the Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) instrument, comparing indirect and direct mapping methods, and the use of FACT-B summary score versus FACT-B subscale scores.
methodsWe used data from three clinical studies for advanced breast cancer providing 11,958 observations with full information on FACT-B and the EQ-5D-3L. We compared direct mapping using adjusted limited dependent variable mixture models (ALDVMMs) with indirect mapping using seemingly unrelated ordered probit models. The EQ-5D-3L was estimated as a function of FACT-B and other patient-related covariates.
resultsThe use of FACT-B subscale scores was better than using the total FACT-B score. A good fit to the observed data was observed across the entire range of disease severity in all models. ALDVMMs outperformed the indirect mapping. The breast cancer-specific scale had a strong influence in predicting the pain/discomfort and self-care dimensions of the EQ-5D-3L.
conclusionsThis article adds to the growing literature that demonstrates the performance of the ALDVMM method for mapping. Regardless of which model is used, the subscales of FACT-B should be included as independent variables wherever possible. The breast cancer-specific subscale of FACT-B is important in predicting the EQ-5D-3L. This suggests that generic cancer measures should not be used for utility mapping in patients with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.